Joan J Albertí

Summary

Publications

  1. doi request reprint Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide
    Joan Alberti
    Department of Pharmacokinetics and Drug Metabolism, Almirall, S A, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Drug Metab Dispos 38:1202-10. 2010
  2. doi request reprint In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism
    Joan J Albertí
    Department of Pharmacokinetics and Drug Metabolism, Almirall, S A, Laurea Miro 408 410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Biochem Pharmacol 81:761-76. 2011
  3. doi request reprint Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)ace
    Maria Prat
    Almirall, R and D Centre, Sant Feliu de Llobregat, Barcelona, Spain
    J Med Chem 52:5076-92. 2009
  4. doi request reprint Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites
    Sonia Sentellas
    Almirall, R and D Center, Sant Feliu de Llobregat, Barcelona, Spain
    Eur J Pharm Sci 39:283-90. 2010

Collaborators

  • Miquel Salva
  • Manuel Ferrer
  • Sonia Sentellas
  • Amadeu Gavaldá
  • Jorge Beleta
  • Montserrat Miralpeix
  • Israel Ramos
  • Francisca Antón
  • Maria Prat
  • Gaspar Casals
  • Hamish Ryder
  • Manuel Lopez
  • Dolors Vilella
  • Laia Tort
  • Josep M Huerta
  • María I Crespo
  • Sonia Espinosa
  • Teresa Domenech
  • Alvaro Cardenas
  • M Antonia Buil
  • Victor Segarra
  • Dolors Fernández
  • Jordi Castro
  • Juan M Monleón
  • Marisa Gonzalez

Detail Information

Publications4

  1. doi request reprint Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide
    Joan Alberti
    Department of Pharmacokinetics and Drug Metabolism, Almirall, S A, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Drug Metab Dispos 38:1202-10. 2010
    ..These results suggest that the potential for clinical interactions involving human cholinesterases is remote at clinically relevant plasma, which are less than 1 nM...
  2. doi request reprint In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism
    Joan J Albertí
    Department of Pharmacokinetics and Drug Metabolism, Almirall, S A, Laurea Miro 408 410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Biochem Pharmacol 81:761-76. 2011
    ....
  3. doi request reprint Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)ace
    Maria Prat
    Almirall, R and D Centre, Sant Feliu de Llobregat, Barcelona, Spain
    J Med Chem 52:5076-92. 2009
    ..Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD...
  4. doi request reprint Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites
    Sonia Sentellas
    Almirall, R and D Center, Sant Feliu de Llobregat, Barcelona, Spain
    Eur J Pharm Sci 39:283-90. 2010
    ..These results suggest that aclidinium may have a reduced systemic exposure and therefore less propensity for class-related systemic side effects in the clinical setting...